Haleen S J, Weishaar R E, Overhiser R W, Bousley R F, Keiser J A, Rapundalo S R, Taylor D G
Department of Pharmacology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Mich. 48105.
Circ Res. 1991 May;68(5):1302-12. doi: 10.1161/01.res.68.5.1302.
The effect of chronic therapy with quinapril on the temporal progression of left ventricular failure and survival was assessed in the CHF 146 cardiomyopathic (CM) hamster, which is an idiopathic model of congestive heart failure. Age-matched Golden Syrian (GS) hamsters served as normal controls. Quinapril was administered in the drinking water at average daily doses of 10.2, 112.4, and 222.4 mg/kg/day. In untreated CM hamsters, in vitro left ventricular performance progressively deteriorated with increasing age beginning at roughly 180 days. This decline in left ventricular performance was accompanied by a decrease in coronary flow and an increase in left ventricular volume. Administration of quinapril from 180 to 300 days of age prevented the decline of in vitro left ventricular contractile performance and coronary flow and also reduced the age-dependent increases in left ventricular volume. The cardioprotective effects of quinapril were observed at doses of 112.4 and 222.4 mg/kg/day but not at 10.2 mg/kg/day. Lung angiotensin converting enzyme activity was significantly inhibited by quinapril in GS and CM hamsters at 240 and 300 days of age at all dose levels. In contrast, significant inhibition of ventricular angiotensin converting enzyme activity was observed consistently at doses of 112.4 and 222.4 mg/kg/day quinapril but not at 10.2 mg/kg/day. In the survival protocol, CM and GS hamsters were treated with vehicle or quinapril (100 mg/kg/day) from 180 to 522 days of age. During the initial 210 days of treatment (from 180 to 390 days of age) 78.3% of the vehicle-treated CM hamsters died compared with 27.7% of quinapril-treated CM hamsters. Quinapril increased the median survival time of CM hamsters by 32.9% (112 days). It is concluded that chronic quinapril therapy exerts a significant cardioprotective effect and also increases survival.
在CHF 146心肌病(CM)仓鼠(一种特发性充血性心力衰竭模型)中评估了喹那普利长期治疗对左心室衰竭时间进程和生存率的影响。年龄匹配的金黄叙利亚(GS)仓鼠作为正常对照。喹那普利以平均每日剂量10.2、112.4和222.4mg/kg/天加入饮用水中给药。在未经治疗的CM仓鼠中,体外左心室功能从大约180天开始随着年龄增长逐渐恶化。左心室功能的这种下降伴随着冠状动脉血流量减少和左心室容积增加。在180至300天龄给予喹那普利可防止体外左心室收缩功能和冠状动脉血流量下降,还可减少左心室容积随年龄的增加。在112.4和222.4mg/kg/天的剂量下观察到喹那普利的心脏保护作用,但在10.2mg/kg/天剂量下未观察到。在240和300天龄时,所有剂量水平的喹那普利均可显著抑制GS和CM仓鼠肺血管紧张素转换酶活性。相比之下,在喹那普利剂量为112.4和222.4mg/kg/天的情况下始终观察到心室血管紧张素转换酶活性受到显著抑制,但在10.2mg/kg/天剂量下未观察到。在生存实验中,CM和GS仓鼠在180至522天龄期间接受赋形剂或喹那普利(100mg/kg/天)治疗。在治疗的最初210天(从180至390天龄),78.3%接受赋形剂治疗的CM仓鼠死亡,而接受喹那普利治疗的CM仓鼠为27.7%。喹那普利使CM仓鼠的中位生存时间增加了32.9%(112天)。得出的结论是,喹那普利长期治疗具有显著的心脏保护作用,还可提高生存率。